CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail order pharmacy, clinical, disease management, and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, CMS, plans offered on public health insurance, and other sponsors of health benefit plans. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, LTC pharmacies and on-site pharmacies, retail specialty pharmacy stores, compounding pharmacies and branches for infusion and enteral nutrition services. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was incorporated in 1996 and is headquartered in Woonsocket, Rhode Island.

CVS Health Corporation

The S&P 500 Index ($SPX) (SPY) Friday closed down -0.01%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.32%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.05%. September E-mini S&P futures (ESU25) fell -0.08%, and September E-mini Nasdaq futures (NQU25) fell -0.10%.
Stocks gave up an early advance on Friday and settled slightly lower on mixed earnings results and weakness in health insurance providers. Netflix fell by more than 5% and weighed on technology stocks after the company forecasted full-year operating margins below consensus.
Join 200K+ Subscribers: Find out why the midday Barchart Brief newsletter is a must-read for thousands daily.
Also, health insurance stocks retreated after Humana lost a lawsuit to reverse cuts to its Medicare bonus payments and after Elevance Health was downgraded.
Stocks maintained slight losses Friday afternoon after the Financial Times reported that President Trump is pushing for a minimum tariff of 15%-20% in any trade deal with the European Union (EU), as Mr. Trump has remained unmoved by the latest EU offer to reduce car tariffs. Also, the Financial Times said that EU trade commissioner Sefcovic gave a downbeat assessment of recent trade talks in Washington on Friday to EU ambassadors.
Stock indexes initially moved higher on Friday, with the S&P 500 and Nasdaq 100 posting new record highs. Bullish factors included the stronger-than-expected housing starts report and generally upbeat earnings reports. Also, the University of Michigan's US July consumer sentiment index rose more than expected to a 5-month high.
Falling bond yields are supportive of stocks following dovish comments from Fed Governor Christopher Waller on Thursday evening, who stated that he supports a Fed interest rate cut at the July 29-30 FOMC meeting. Also, an easing of inflation expectations in Friday's University of Michigan's July inflation expectations report was bullish for T-notes and stocks. The 10-year T-note yield fell -2 bp to 4.43%.
US June housing starts rose +4.6% m/m to 1.321 million, stronger than expectations of 1.300 million. Also, June building permits, a proxy for future construction, unexpectedly rose +0.2% m/m to 1.397 million versus expectations of a -0.5% m/m decline to 1.387 million.
The University of Michigan's July US consumer sentiment index rose +1.1 to a 5-month high of 61.8, stronger than expectations of 61.5.
The University of Michigan's US July 1-year inflation expectations indicator fell to a 5-month low of +4.4%, better than expectations of no change at +5.0%. Also, the July 5-10 year inflation expectations indicator eased to a 5-month low of +3.6%, weaker than expectations of +3.9%.
Thursday evening, Fed Governor Christopher Waller said, "With inflation near target and the upside risks to inflation limited, we should not wait until the labor market deteriorates before we cut the policy rate. I believe it makes sense to cut the FOMC's policy rate by 25 basis points two weeks from now."
Recent trade news has put some downward pressure on stocks. President Trump said late Wednesday that he intends to send a tariff letter to more than 150 countries notifying them their tariff rates could be 10% or 15%, effective August 1, and that the group was "not big countries who don't do that much business with the US."
Also, President Trump last weekend announced that the US will impose 30% tariffs on US imports from the European Union and Mexico, effective August 1. Mr. Trump said last Thursday that a 35% tariff on some Canadian products would take effect on August 1, up from the current 25%. Last week, Mr. Trump imposed a 50% tariff on copper imports, which will include semi-finished goods, and stated that drug companies could face tariffs as high as 200% on imports if they don't relocate production to the US within the next year.
Federal funds futures prices are discounting the chances for a -25 bp rate cut at 5% at the July 29-30 FOMC meeting and 58% at the following meeting on September 16-17.
Earnings season began in earnest this week as big bank earnings results came in stronger than expected. Early results now show S&P 500 earnings are on track to rise +3.2% for the second quarter, better than the pre-season expectations of +2.8% y/y, according to Bloomberg Intelligence. Also, only six of the eleven S&P 500 sectors are projected to post an increase in earnings, the fewest since Q1 of 2023, according to Yardeni Research.
Overseas stock markets on Friday settled mixed. The Euro Stoxx 50 closed down -0.33%. China's Shanghai Composite closed up +0.50%. Japan's Nikkei Stock 225 fell from a 2.5-week high and closed down -0.21%.
Interest Rates
September 10-year T-notes (ZNU25) on Friday closed up +8.5 ticks. The 10-year T-note yield fell -2.3 bp to 4.428%. T-notes rose Friday on dovish comments from Fed Governor Christopher Waller, who said he backs a Fed rate cut at the July 29-30 FOMC meeting. Also, falling inflation expectations in Friday's University of Michigan report were bullish for T-notes.
On the bearish side, Friday's US housing starts report was stronger than expected. Also, Friday's increase in the University of Michigan US July consumer sentiment to a 5-month high was negative for T-notes.
European government bond yields on Friday moved higher. The 10-year German bund yield rose +2.0 bp to 2.695%. The 10-year UK gilt yield climbed to a 1.5-month high of 4.684% and finished up +1.9 bp to 4.674%.
Eurozone May construction output fell -1.7% m/m, the biggest decline in nearly 2.5-years.
The German June PPI fell -1.3% y/y, right on expectations and the steepest pace of decline in 9 months.
Swaps are discounting the chances at 1% for a -25 bp rate cut by the ECB at the July 24 policy meeting.
US Stock Movers
Weakness in managed health care stocks weighed on the broader market Friday. Molina Healthcare (MOH) closed down more than -10% to lead losers in the S&P 500, and Elevance Health (ELV) closed down more than -8% after Leerink Partners downgraded the stock to market perform from outperform. Also, Centene (CNC) closed down more than -3%, and CVS Health Corp (CVS) and UnitedHealth Group (UNH) closed down more than -2%. In addition, Humana (HUM) closed down more than -1% after it lost a lawsuit seeking to reverse cuts to its Medicare bonus payments.
Netflix (NFLX) closed down more than -5% after forecasting a full-year operating margin of 29.5%, below the consensus of 29.7%.
3M Co (MMM) closed down more than -3% to lead losers in the Dow Jones Industrials after cutting its full-year organic sales estimate to +2% from a previous forecast of +2% to +3%.
Sarepta Therapeutics (SRPT) closed down more than -36% after it said another patient died from acute liver failure after receiving one of its experimental gene therapies for a muscle disease.
Autoliv (ALV) closed down more than -4% after reporting Q2 adjusted operating margin of 9.30%, below the consensus of 9.35%.
Builders FirstSource (BLDR) closed down more than -3% after Zelman & Associates downgraded the stock to underperform.
American Express (AXP) closed down more than -2% after reporting Q2 total expenses of $12.90 billion, above the consensus of $12.73 billion.
Talen Energy (TLN) closed up more than +24% after acquiring gas-fired power plants in Pennsylvania and Ohio for $3.5 billion.
Invesco Ltd (IVZ) closed up more than +15% to lead gainers in the S&P 500 after it filed a proxy statement with the SEC seeking to convert the Invesco QQQ Trust Series 1 into an open-ended fund from a unit investment trust.
Interactive Brokers Group (IBKR) closed up more than +7% after reporting Q2 total net interest income of $860 million, well above the consensus of $794.7 million.
Regions Financial (RF) closed up more than +6% after reporting Q2 net interest income of $1.27 billion, better than the consensus of $1.24 billion, and raising its full-year net interest income growth estimate to +3% to +5% from a previous estimate of +1% to +4%.
Abbott Laboratories (ABT) closed up more than +2% after Jefferies upgraded the stock to buy from hold with a price target of $145.
Norfolk Southern (NSC) closed up more than +2% on reports that Union Pacific is said to be exploring an acquisition of the company.
Charles Schwab (SCHW) closed up more than +2% after reporting Q2 net revenue of $5.85 billion, stronger than the consensus of $5.72 billion.
Earnings Reports (7/21/2025)
AGNC Investment Corp (AGNC), Alexandria Real Estate Equities (ARE), BOK Financial Corp (BOKF), Cleveland-Cliffs Inc (CLF), Crown Holdings Inc (CCK), Domino's Pizza Inc (DPZ), Equity LifeStyle Properties In (ELS), Medpace Holdings Inc (MEDP), NXP Semiconductors NV (NXPI), RLI Corp (RLI), Roper Technologies Inc (ROP), Steel Dynamics Inc (STLD), Verizon Communications Inc (VZ), W R Berkley Corp (WRB), Wintrust Financial Corp (WTFC), Zions Bancorp NA (ZION).
On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Stocks Finish Slightly Lower on Mixed Earnings Results

CVS Health (CVS) closed the most recent trading day at $61.96, moving -2.12% from the previous trading session. This change lagged the S&P 500's 0.01% loss on the day. Elsewhere, the Dow lost 0.32%, while the tech-heavy Nasdaq added 0.05%.
The drugstore chain and pharmacy benefits manager's stock has dropped by 5.3% in the past month, falling short of the Medical sector's loss of 1.59% and the S&P 500's gain of 5.37%.
Investors will be eagerly watching for the performance of CVS Health in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on July 31, 2025. It is anticipated that the company will report an EPS of $1.47, marking a 19.67% fall compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $93.72 billion, up 2.73% from the prior-year quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $6.12 per share and revenue of $385.5 billion, indicating changes of +12.92% and +3.4%, respectively, compared to the previous year.
Investors should also take note of any recent adjustments to analyst estimates for CVS Health. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.32% higher. CVS Health presently features a Zacks Rank of #2 (Buy).
Valuation is also important, so investors should note that CVS Health has a Forward P/E ratio of 10.35 right now. This indicates a discount in contrast to its industry's Forward P/E of 15.4.
Meanwhile, CVS's PEG ratio is currently 0.91. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical Services was holding an average PEG ratio of 1.52 at yesterday's closing price.
The Medical Services industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 90, placing it within the top 37% of over 250 industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include
Stock #1: A Disruptive Force with Notable Growth and Resilience
Stock #2: Bullish Signs Signaling to Buy the Dip
Stock #3: One of the Most Compelling Investments in the Market
Stock #4: Leader In a Red-Hot Industry Poised for Growth
Stock #5: Modern Omni-Channel Platform Coiled to Spring
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.
Download Atomic Opportunity: Nuclear Energy's Comeback free today.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

CVS Health (CVS) Dips More Than Broader Market: What You Should Know

The S&P 500 Index ($SPX) (SPY) today down -0.08%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.44%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.15%. September E-mini S&P futures (ESU25) are down -0.14%, and September E-mini Nasdaq futures (NQU25) are down -0.17%.
Stocks today gave up an early advance and turned lower as a -5% decline in Netflix weighed on technology stocks after the company forecasted below-consensus full-year operating margins. Also, the weakness in health insurance providers is weighing on the broader market today after Humana lost a lawsuit to reverse cuts to its Medicare bonus payments and after Elevance Health was downgraded.
Join 200K+ Subscribers: Find out why the midday Barchart Brief newsletter is a must-read for thousands daily.
Stock indexes initially moved higher, with the S&P 500 and Nasdaq 100 posting new record highs. Bullish factors included the stronger-than-expected housing starts report and generally upbeat earnings reports. Also, the University of Michigan’s US July consumer sentiment index rose more than expected to a 5-month high.
Falling bond yields are supportive of stocks following dovish comments from Fed Governor Christopher Waller on Thursday evening, who stated that he supports a Fed interest rate cut at the July 29-30 FOMC meeting. Also, an easing of inflation expectations in today’s University of Michigan’s July inflation expectations report was bullish for T-notes and stocks. The 10-year T-note yield is down -3 bp to 4.42%.
US June housing starts rose +4.6% m/m to 1.321 million, stronger than expectations of 1.300 million. Also, June building permits, a proxy for future construction, unexpectedly rose +0.2% m/m to 1.397 million versus expectations of a -0.5% m/m decline to 1.387 million.
The University of Michigan’s July US consumer sentiment index rose +1.1 to a 5-month high of 61.8, stronger than expectations of 61.5.
The University of Michigan’s US July 1-year inflation expectations indicator fell to a 5-month low of +4.4%, better than expectations of no change at +5.0%. Also, the July 5-10 year inflation expectations indicator eased to a 5-month low of +3.6%, weaker than expectations of +3.9%.
Thursday evening, Fed Governor Christopher Waller said, “With inflation near target and the upside risks to inflation limited, we should not wait until the labor market deteriorates before we cut the policy rate. I believe it makes sense to cut the FOMC’s policy rate by 25 basis points two weeks from now.”
Recent trade news has put some downward pressure on stocks. President Trump said late Wednesday that he intends to send a tariff letter to more than 150 countries notifying them their tariff rates could be 10% or 15%, effective August 1, and that the group was “not big countries who don’t do that much business with the US.”
Also, President Trump last weekend announced that the US will impose 30% tariffs on US imports from the European Union and Mexico, effective August 1. Mr. Trump said last Thursday that a 35% tariff on some Canadian products would take effect on August 1, up from the current 25%. Last week, Mr. Trump imposed a 50% tariff on copper imports, which will include semi-finished goods, and stated that drug companies could face tariffs as high as 200% on imports if they don’t relocate production to the US within the next year.
Federal funds futures prices are discounting the chances for a -25 bp rate cut at 5% at the July 29-30 FOMC meeting and 58% at the following meeting on September 16-17.
Earnings season began in earnest this week as big bank earnings results came in stronger than expected. Early results now show S&P 500 earnings are on track to rise +3.2% for the second quarter, better than the pre-season expectations of +2.8% y/y, according to Bloomberg Intelligence. Also, only six of the eleven S&P 500 sectors are projected to post an increase in earnings, the fewest since Q1 of 2023, according to Yardeni Research.
Overseas stock markets today are mixed. The Euro Stoxx 50 is down -0.42%. China’s Shanghai Composite closed up +0.50%. Japan’s Nikkei Stock 225 fell from a 2.5-week high and closed down -0.21%.
Interest Rates
September 10-year T-notes (ZNU25) today are up +9 ticks. The 10-year T-note yield is down -2.0 bp to 4.432%. T-notes are climbing today on dovish comments from Fed Governor Christopher Waller, who said he backs a Fed rate cut at the July 29-30 FOMC meeting. Also, falling inflation expectations in today’s University of Michigan report were bullish for T-notes.
On the bearish side, today’s US housing starts report was stronger than expected. Also, today’s increase in the University of Michigan US July consumer sentiment to a 5-month high was negative for T-notes.
European government bond yields today are moving higher. The 10-year German bund yield is up +2.1 bp to 2.696%. The 10-year UK gilt yield climbed to a 1.5-month high of 4.680% and is up +2.1 bp to 4.676%.
Eurozone May construction output fell -1.7% m/m, the biggest decline in nearly 2.5-years.
The German June PPI fell -1.3% y/y, right on expectations and the steepest pace of decline in 9 months.
Swaps are discounting the chances at 1% for a -25 bp rate cut by the ECB at the July 24 policy meeting.
US Stock Movers
Weakness in managed health care stocks is weighing on the broader market today. Elevance Health (ELV) is down more than -5% to lead losers in the S&P 500 after Leerink Partners downgraded the stock to market perform from outperform. Also, Humana (HUM) is down more than -2% after it lost a lawsuit seeking to reverse cuts to its Medicare bonus payments. In addition, Molina Healthcare (MOH) is down more than -4%, and Centene (CNC) and CVS Health Corp (CVS) are down more than -1%.
Netflix (NFLX) is down more than -5% to lead losers in the Nasdaq 100 after forecasting a full-year operating margin of 29.5%, below the consensus of 29.7%.
American Express (AXP) is down more than -3% to lead losers in the Dow Jones Industrials after reporting Q2 total expenses of $12.90 billion, above the consensus of $12.73 billion.
3M Co (MMM) is down more than -3% after cutting its full-year organic sales estimate to +2% from a previous forecast of +2% to +3%.
Sarepta Therapeutics (SRPT) is down more than -18% after it said another patient died from acute liver failure after receiving one of its experimental gene therapies for a muscle disease.
Autoliv (ALV) is down more than -4% after reporting Q2 adjusted operating margin of 9.30%, below the consensus of 9.35%.
Builders FirstSource (BLDR) is down more than -2% after Zelman & Associates downgraded the stock to underperform.
Talen Energy (TLN) is up more than +22% after acquiring gas-fired power plants in Pennsylvania and Ohio for $3.5 billion.
Invesco Ltd (IVZ) is up more than +11% to lead gainers in the S&P 500 after it filed a proxy statement with the SEC seeking to convert the Invesco QQQ Trust Series 1 into an open-ended fund from a unit investment trust.
Interactive Brokers Group (IBKR) is up more than +6% after reporting Q2 total net interest income of $860 million, well above the consensus of $794.7 million.
Regions Financial (RF) is up more than +4% after reporting Q2 net interest income of $1.27 billion, better than the consensus of $1.24 billion, and raising its full-year net interest income growth estimate to +3% to +5% from a previous estimate of +1% to +4%.
Abbott Laboratories (ABT) is up more than +3% after Jefferies upgraded the stock to buy from hold with a price target of $145.
Norfolk Southern (NSC) is up more than +3% on reports that Union Pacific is said to be exploring an acquisition of the company.
Charles Schwab (SCHW) is up more than +2% after reporting Q2 net revenue of $5.85 billion, stronger than the consensus of $5.72 billion.
Earnings Reports (7/18/2025)
3M Co (MMM), Ally Financial Inc (ALLY), American Express Co (AXP), Charles Schwab Corp/The (SCHW), Comerica Inc (CMA), Euronet Worldwide Inc (EEFT), Huntington Bancshares Inc/OH (HBAN), MarketAxess Holdings Inc (MKTX), Regions Financial Corp (RF), Schlumberger NV (SLB), Southern Copper Corp (SCCO), Truist Financial Corp (TFC).
On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Stocks Pressured by Weakness in Netflix and Health Insurers

Healthcare plan provider, Molina Healthcare, Inc. MOH, is set to report second-quarter 2025 results on July 23, 2025, after the closing bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is currently pegged at $5.56 per shareon revenues of $10.84 billion.
The second-quarter earnings estimate witnessed three downward revisions over the past week against no movement in the opposite direction. The bottom-line projection indicates a year-over-year decrease of 5.1%. However, the Zacks Consensus Estimate for quarterly revenues suggests year-over-year growth of 9.7%.
Image Source: Zacks Investment Research
For full-year 2025, the Zacks Consensus Estimate for Molina Healthcare’s revenues is pegged at $44.06 billion, implying a rise of 8.4% year over year. However, the consensus mark for 2025 earnings per share is pegged at $22.58, indicating a decline of 0.3% on a year-over-year basis. (See the Zacks Earnings Calendar to stay ahead of market-making news.)
Molina Healthcare beat the consensus estimate in three of the last four quarters and missed once, with the average surprise being negative 1.6%. This is depicted in the figure below.
Molina Healthcare, Inc Price and EPS Surprise
Q2 Earnings Whispers for MOH
Our proven model does not conclusively predict an earnings beat for the company this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat. That’s not the case here.
MOH has an Earnings ESP of -1.09% and carries a Zacks Rank #5 (Strong Sell). You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
What’s Shaping MOH’s Q2 Results?
The Zacks Consensus Estimate for premiums indicates growth of 10.1% year over year in the second quarter, while our model estimate suggests a 7.4% increase. We expect Medicaid premiums to grow 4.1% year over year in the to-be-reported quarter. The consensus estimate for the Medicare premiums is $1.5 billion, up 1.9% year over year.
Earlier this month, the company pointed out a dislocation between premium rate growth and the accelerating medical cost trend. An aging U.S. population is likely to have sustained the solid demand for its Medicare plans in the second quarter. The Medicaid membership growth is likely to have been offset by the redetermination process.
Medicaid membership is expected to have decreased 1.2% year over year, while MOH’s Medicare membership is projected to witness 4.2% growth. Furthermore, the Zacks Consensus Estimate for the Marketplace membership suggests a 63% increase from the year-ago period.
However, the consensus mark for medical care ratio (MCR) in Marketplace is pegged at 77.49% in the to-be-reported quarter, up from 71.60% a year ago. The consensus mark for total MCR is pegged at 88.86%, up from 88.60% a year ago.
Along with this, rising costs and lower investment income make an earnings beat uncertain. The Zacks Consensus Estimate for investment income indicates a 12.1% decline year over year. Our model estimate for second quarter total operating expenses predicts a more than 8% increase from the year-ago period, due to higher medical care costs and G&A expenses. The company expects its adjusted net income to be around $295 million in the quarter, a decline of 13.5% from a year ago.
Stocks That Warrant a Look
While an earnings beat looks uncertain for Molina Healthcare, here are some companies from the broader Medical space that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this time around:
Boston Scientific Corporation BSX has an Earnings ESP of +0.88% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Boston Scientific’s bottom line for the to-be-reported quarter indicates 16.1% year-over-year growth. Boston Scientific’s earnings beat estimates in each of the last four quarters, with an average surprise of 8.8%.
CVS Health Corporation CVS has an Earnings ESP of +2.06% and a Zacks Rank of 2.
The Zacks Consensus Estimate for CVS Health’s bottom line for the to-be-reported quarter is pegged at $1.47. CVS Health’s earnings beat estimates in each of the past four quarters, with an average surprise of 18.1%.
Cencora, Inc. COR has an Earnings ESP of +1.49% and a Zacks Rank of 2.
The Zacks Consensus Estimate for Cencora’s bottom line for the to-be-reported quarter indicates 13.2% year-over-year growth. Cencora’s earnings beat estimates in each of the trailing four quarters, with an average surprise of 6%.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include
Stock #1: A Disruptive Force with Notable Growth and Resilience
Stock #2: Bullish Signs Signaling to Buy the Dip
Stock #3: One of the Most Compelling Investments in the Market
Stock #4: Leader In a Red-Hot Industry Poised for Growth
Stock #5: Modern Omni-Channel Platform Coiled to Spring
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.
Download Atomic Opportunity: Nuclear Energy's Comeback free today.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Molina to Report Q2 Earnings: Healthy Revenues, Weak Pulse on Earnings

Danaher Corporation DHR is scheduled to release second-quarter 2025 results on July 22, before market open.
The Zacks Consensus Estimate for revenues is pegged at $5.84 billion, which indicates an increase of 1.6% from the year-ago quarter’s figure. The consensus mark for earnings is pinned at $1.64 per share, which has remained steady in the past 30 days. The estimate indicates a decrease of 4.7% from the figure reported in the year-ago quarter. The company’s bottom line surpassed the Zacks Consensus Estimate in three of the preceding four quarters while missing the mark in one, the average beat being 8.5%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
Let’s see how things have shaped up for Danaher this earnings season.
Key Factors and Estimates for Q2
Weakness in Danaher’s protein consumables, flow cytometry and lab automation solutions businesses, due to lower demand across academic and government end-markets, is likely to have hurt the Life Sciences segment’s revenues in the second quarter. Also, sales decline in the filtration business due to soft demand in the energy-related end market is likely to have impacted the segment’s performance. We expect the segment’s revenues to decrease 3.4% from the year-ago quarter to $1.71 billion.
DHR has been witnessing escalating SG&A expenses, which are likely to weigh on its bottom-line results. For the quarter under review, we anticipate SG&A expenses to be $1.55 billion, indicating a 5.8% increase from the year-earlier level.
The company has considerable exposure to overseas markets. Given its substantial international operations, foreign currency headwinds are likely to have marred its profitability.
However, strength in the bioprocessing business, driven by an increase in demand for consumables from large pharmaceutical customers in North America, Europe and Southeast Asia, is expected to have aided the Biotechnology segment. The segment’s performance is also likely to have benefited from solid momentum in the discovery and medical business. We expect the segment’s revenues to increase 7% from the year-ago quarter to $1.83 billion.
Solid momentum in the pathology and acute care diagnostics businesses is expected to drive the Diagnostics segment’s results. We expect the segment’s revenues to increase 1.1% from the year-ago quarter to $2.29 billion.
Danaher acquired Abcam plc, a global supplier of protein consumables, in December 2023, which expanded the Life Sciences segment. Abcam's long track record of innovation, outstanding product quality and breadth of antibody portfolio are expected to have helped the company solve some pertinent healthcare challenges.
Danaher Corporation Price and EPS Surprise
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for DHR this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here, as elaborated below.
Earnings ESP: DHR has an Earnings ESP of 0.00% as both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at $1.64 per share. You can uncover the best stocks before they’re reported with our Earnings ESP Filter.
Zacks Rank: DHR presently carries a Zacks Rank #4 (Sell).
Stocks to Consider
Here are some companies within the broader Medical sector, which according to our model, have the right combination of elements to beat on earnings in this reporting cycle.
CVS Health Corporation CVS has an Earnings ESP of +2.06% and a Zacks Rank of 2 at present. The company is slated to release second-quarter 2025 results on July 31.
CVS Health’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 18.1%.
Cencora, Inc. COR has an Earnings ESP of +1.49% and a Zacks Rank of 2 at present. The company is scheduled to release second-quarter 2025 results on Aug. 6.
Cencora’s earnings surpassed the Zacks Consensus Estimate in each of the preceding four quarters, the average surprise being 6%.
Amgen Inc. AMGN has an Earnings ESP of +0.07% and a Zacks Rank of 3 at present. The company is slated to release second-quarter 2025 results on Aug. 5.
Amgen’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 8.3%.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include
Stock #1: A Disruptive Force with Notable Growth and Resilience
Stock #2: Bullish Signs Signaling to Buy the Dip
Stock #3: One of the Most Compelling Investments in the Market
Stock #4: Leader In a Red-Hot Industry Poised for Growth
Stock #5: Modern Omni-Channel Platform Coiled to Spring
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.
Download Atomic Opportunity: Nuclear Energy's Comeback free today.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Danaher Gears Up to Post Q2 Earnings: What Lies Ahead for the Stock?

Looking at the universe of stocks we cover at Dividend Channel, on 7/22/25, CVS Health Corporation (Symbol: CVS) will trade ex-dividend, for its quarterly dividend of $0.665, payable on 8/1/25. As a percentage of CVS's recent stock price of $63.30, this dividend works out to approximately 1.05%, so look for shares of CVS Health Corporation to trade 1.05% lower — all else being equal — when CVS shares open for trading on 7/22/25.
In general, dividends are not always predictable; but looking at the history above can help in judging whether the most recent dividend from CVS is likely to continue, and whether the current estimated yield of 4.20% on annualized basis is a reasonable expectation of annual yield going forward. The chart below shows the one year performance of CVS shares, versus its 200 day moving average:
Looking at the chart above, CVS's low point in its 52 week range is $43.56 per share, with $72.51 as the 52 week high point — that compares with a last trade of $63.21.
Free Report: Top 8%+ Dividends (paid monthly)
In Friday trading, CVS Health Corporation shares are currently down about 0.8% on the day.
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »
CAR Average Annual Return
ETFs Holding AREX
ABST Videos
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Reminder - CVS Health Goes Ex-Dividend Soon

Thermo Fisher Scientific Inc. TMO is slated to release second-quarter 2025 results on July 23, before market open.
Thermo Fisher’s first-quarter earnings of $5.15 per share beat the Zacks Consensus Estimate by 1%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 2.28%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
TMO’s Q2 Estimates
The Zacks Consensus Estimate for revenues is pegged at $10.65 billion, suggesting a 1% rise from the prior-year quarter’s reported figure. The consensus mark for earnings is pegged at $5.22 per share, indicating a 2.8% decline from the year-ago quarter’s reported numbers.
Estimate Revision Trend Ahead of Earnings
Estimates for Thermo Fisher’s second-quarter earnings have remained unchanged at $5.22 per share in the past 60 days.
Now, let's take a look at how things might have progressed for the MedTech major prior to the announcement.
Factors at Play
Thermo Fisher’s Analytical Instruments segment is expected to have generated strong sales, banking on its electron microscopy and chromatography and mass spectrometry businesses. In the second quarter, the company launched Krios 5 Cryo-TEM, a next-generation, atomic-resolution platform that leverages enhanced optics and AI-enabled automation to study molecular structures and interactions. It also launched the Invitrogen Attune Xenith Flow Cytometer, offering increased speed, versatility and reliability to labs. Meanwhile, TMO launched TruNarc Delta and Tau Handheld Narcotics Analyzers to help communities combat emerging narcotics and illicit substances.
In the first quarter of 2025, Thermo Fisher had several newly launched cutting-edge technologies. Within electron microscopy, the company launched Vulcan Automated Lab, a fully-integrated AI-enabled solution that combines robotics and electron microscopy, helping advance process development and control in semiconductor manufacturing.
Additionally, in the chromatography and mass spectrometry arm, it launched Transcend, a new ultra-high performance liquid chromatography platform that helps high-volume laboratories simplify sample preparation and increase efficiency in clinical research, food safety and environmental testing applications. We expect these developments to have contributed to TMO’s second-quarter revenues.
Per our model, Thermo Fisher’s Analytical Instruments business should post $1.84 billion in revenues, suggesting 3.3% growth year over year.
Within the Life-Science Solutions segment, the company is likely to have experienced sales growth, banking on its bioproduction business. In the second quarter, the Olink Explore HT proteomics platform was selected by the Regeneron Genetics Center for a large-scale proteomics investigation that aims to unlock new insights into the dynamic biology and mechanisms of human disease. Thermo Fisher opened Advanced Therapies Collaboration Center (ATxCC) in Carlsbad, CA, to accelerate the development and commercialization of cell therapies.
Also, in the previous quarter, TMO launched Olink Reveal, an affordable, high-plex proteomics that enables researchers to identify circulating biomarkers for a range of applications with reduced cost and set up requirements. These developments might have turned in favor of Thermo Fisher in the to-be-reported quarter.
Per our model, the Life-Science Solutions business is expected to report $2.37 billion in second-quarter revenues, calling for a 0.5% improvement year over year.
The Specialty Diagnostics segment (Clinical Diagnostics business from the molecular controls that go into testing kits) is likely to have gained positive contributions, led by its transplant diagnostics and immunodiagnostics businesses as well as the healthcare market channel. Additionally, during the first quarter, the company launched CorEvitas patient registries in adolescent alopecia areata and lupus erythematosus to improve patient outcomes. We expect this to have had a positive impact on the company’s second-quarter top-line performance.
Thermo Fisher Scientific Inc. Price and EPS Surprise
Our model projects TMO’s Specialty Diagnostics business to report $1.15 billion in revenues, suggesting 2.9% growth year over year.
Within the Laboratory Products and Services segment, revenues are expected to have increased due to the pharma services business as well as the research and safety market channel. Also, TMO launched 5L DynaDrive Single-Use Bioreactor (S.U.B.), offering seamless scalability from 1 to 5,000 liters and accelerating bench-scale process development, to meet the evolving needs of modern bioprocessing. In the previous quarter, it launched new lines of floor-model centrifuges — Thermo Scientific Cryofuge, Thermo Scientific BIOS and Thermo Scientific LYNX — to provide more sustainable solutions without compromising performance and sample security. These, too, might have had a favorable impact on TMO’s top line in the to-be-reported quarter.
Our model expects Laboratory Products and Services business second-quarter revenues to be $5.71 billion, suggesting a decline of 0.7% year over year.
What Our Quantitative Model Predicts
Per our proven model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.
Earnings ESP: Thermo Fisher has an Earnings ESP of -0.35%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Top MedTech Picks
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle:
CVS Health CVS has an Earnings ESP of +2.06% and a Zacks Rank #2 at present. The company is slated to release second-quarter 2025 results on July 31. You can see the complete list of today’s Zacks #1 Rank stocks here.
CVS’ earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.08%. The Zacks Consensus Estimate for second-quarter EPS implies a year-over-year decline of 19.7%.
Cencora COR has an Earnings ESP of +1.49% and a Zacks Rank #2 at present. The company is slated to release third-quarter fiscal 2025 results on Aug. 6.
The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.00%. The Zacks Consensus Estimate for fiscal third-quarter EPS implies a year-over-year increase of 13.2%.
Cardinal Health CAH has an Earnings ESP of +0.68% and a Zacks Rank #2 at present. The company is expected to release fiscal fourth-quarter 2025 results soon.
CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.30%. The Zacks Consensus Estimate for fiscal fourth-quarter EPS suggests a year-over-year improvement of 1.3%.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include
Stock #1: A Disruptive Force with Notable Growth and Resilience
Stock #2: Bullish Signs Signaling to Buy the Dip
Stock #3: One of the Most Compelling Investments in the Market
Stock #4: Leader In a Red-Hot Industry Poised for Growth
Stock #5: Modern Omni-Channel Platform Coiled to Spring
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.
Download Atomic Opportunity: Nuclear Energy's Comeback free today.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

TMO to Report Q2 Earnings: Analytical Instruments Segment in Focus

Rising prescription drug costs remain a top healthcare concern, with pharmacy benefit managers (PBMs) facing heightened scrutiny for their role in managing prescription drug benefits for insurers and health plans. CVS Health’s CVS Caremark business recently secured a new pharmacy benefits contract with The California Public Employees’ Retirement System (CalPERS) — the largest public pension fund in the United States. The five-year agreement replaces OptumRx, UnitedHealth Group’s UNH PBM, which had served CalPERS members over the past nine years.
Starting Jan. 1, 2026, Caremark will provide outpatient prescription drug benefits to nearly 587,000 members enrolled in Basic or Medicare HMO and PPO plans, which is roughly 40% of CalPERS’ 1.5 million beneficiaries. CVS will also work closely with CalPERS to develop a range of options for managing formulary changes that could affect copays or require switching to an equally effective alternative.
Essentially, CVS Caremark was selected over other vendors for its ability to deliver more affordable drug benefits, and its commitment to strong contract terms around accountability, transparency and groundbreaking financial guarantees. The company puts $250 million at risk if it fails to meet targets for controlling pharmacy benefit costs and delivering clinical quality outcomes tied to improving care for high blood pressure and diabetes. The contract positions CVS Caremark at the forefront of CalPERS’ efforts to create a model that can serve as “a blueprint for purchasers nationwide”.
This year, CVS Health also opted to prefer Wegovy over Zepbound on its commercial template formularies. The move is designed to promote competition in reducing drug costs and enable broader, more affordable coverage for weight management medications. Clients using CVS Caremark’s template formularies could save 10-15% annually in the anti-obesity medication space as a result of this strategic change.
Updates From CVS Health’s PBM Peers
The global PBM market is expanding, with CVS Caremark, OptumRx and Express Scripts (Cigna) dominating the market. Other prominent players include Elevance Health ELV, which offers pharmacy services through its CarelonRx unit. ELV had just released its second quarter-2025 earnings results, with higher CarelonRx product revenues driving a 33% year-over-year increase in Carelon operating gains. The growth in CarelonRx operating revenues was mainly due to higher prescription volume from rising pharmacy membership and contributions from recent acquisitions.
Humana HUM, too, operates a PBM business under its Insurance segment. Humana recently announced a partnership with healthcare software company Epic, becoming the first health insurer to integrate health plan information directly into the MyChart accounts. This enables Humana Medicare Advantage members to access their insurance details, such as vital coverage information, benefits, contacts and other resources, in the same platform where they manage the rest of their care.
CVS’ Price Performance, Valuation and Estimates
In the past year, CVS Health shares have risen 6.3% against the industry’s 17.7% fall.
Image Source: Zacks Investment Research
CVS shares are trading at a forward one-year price-to-earnings ratio of 9.60 compared to the industry average of 14.00. The stock carries a Value Score of A.
Image Source: Zacks Investment Research
Analyst estimates for the company’s 2025 and 2026 earnings are showing an upward trend.
Image Source: Zacks Investment Research
CVS stock currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include
Stock #1: A Disruptive Force with Notable Growth and Resilience
Stock #2: Bullish Signs Signaling to Buy the Dip
Stock #3: One of the Most Compelling Investments in the Market
Stock #4: Leader In a Red-Hot Industry Poised for Growth
Stock #5: Modern Omni-Channel Platform Coiled to Spring
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.
Download Atomic Opportunity: Nuclear Energy's Comeback free today.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

CVS Health's Caremark to Lead CalPERS' PBM Vision: What's at Stake?

Elevance Health (NYSE:ELV) is scheduled to announce its earnings on Thursday, July 17, 2025. For event-driven traders, examining historical stock performance around earnings releases can provide valuable insights and potentially enhance trading strategies.
Over the past five years, ELV has demonstrated positive one-day stock returns in 55% of instances following earnings reports. The median positive return on these days was 2.7%, with a maximum one-day positive return reaching 7.7%. Separately, cryptocurrencies have started to move again. See Will The Rally In XRP Price Continue?
Traders can approach earnings announcements with two main strategies:
Pre-Earnings Positioning: Based on the historical probabilities, one might consider establishing a position before the earnings report is released.
Post-Earnings Positioning: Alternatively, traders can wait for the earnings announcement and then analyze the relationship between immediate and medium-term returns to guide their subsequent trading decisions.
Analysts’ consensus estimates for Elevance Health’s upcoming report are earnings of $9.19 per share on revenue of $48.26 billion. This is in contrast to the year-ago quarter, where the company reported earnings of $10.12 per share on revenue of $43.22 billion.
From a fundamental standpoint, Elevance Health currently holds a market capitalization of $77 billion. Over the last twelve months, the company generated $183 billion in revenue and reported a net income of $5.9 billion.
That said, if you seek upside with lower volatility than individual stocks, the Trefis High Quality portfolio presents an alternative — having outperformed the S&P 500 and generated returns exceeding 91% since its inception. Also, see the potential for growth in Google Stock To $350?
See earnings reaction history of all stocks
Elevance Health’s Historical Odds Of Positive Post-Earnings Return
Some observations on one-day (1D) post-earnings returns:
There are 18 earnings data points recorded over the last five years, with 11 positive and 7 negative one-day (1D) returns observed. In summary, positive 1D returns were seen about 61% of the time.
Notably, this percentage increases to 73% if we consider data for the last 3 years instead of 5.
Median of the 11 positive returns = 2.7%, and median of the 7 negative returns = -5.3%
Additional data for observed 5-Day (5D), and 21-Day (21D) returns post earnings are summarized along with the statistics in the table below.
Correlation Between 1D, 5D, and 21D Historical Returns
A relatively less risky strategy (though not useful if the correlation is low) is to understand the correlation between short-term and medium-term returns post earnings, find a pair that has the highest correlation, and execute the appropriate trade. For example, if 1D and 5D show the highest correlation, a trader can position themselves “long” for the next 5 days if 1D post-earnings return is positive. Here is some correlation data based on 5-year and 3-year (more recent) history. Note that the correlation 1D_5D refers to the correlation between 1D post-earnings returns and subsequent 5D returns.
Learn more about Trefis RV strategy that has outperformed its all-cap stocks benchmark (combination of all 3, the S&P 500, S&P mid-cap, and Russell 2000), to produce strong returns for investors. Separately, if you want upside with a smoother ride than an individual stock like Elevance Health, consider the High Quality portfolio, which has outperformed the S&P, and clocked >91% returns since inception.
Invest with Trefis Market-Beating Portfolios
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

How Will Elevance Health Stock React To Its Upcoming Earnings?

The NASDAQ 100 After Hours Indicator is down -4.63 to 22,851. The total After hours volume is currently 99,204,064 shares traded.
The following are the most active stocks for the after hours session:
Intel Corporation (INTC) is unchanged at $23.30, with 4,600,444 shares traded. INTC's current last sale is 110.95% of the target price of $21.
Transocean Ltd. (RIG) is -0.0293 at $2.71, with 3,736,263 shares traded. RIG's current last sale is 60.24% of the target price of $4.5.
Advanced Micro Devices, Inc. (AMD) is -0.2375 at $146.00, with 3,231,884 shares traded. As reported by Zacks, the current mean recommendation for AMD is in the "buy range".
Palantir Technologies Inc. (PLTR) is -0.31 at $148.84, with 3,188,598 shares traded., following a 52-week high recorded in today's regular session.
Cisco Systems, Inc. (CSCO) is -0.05 at $67.77, with 3,137,664 shares traded. As reported by Zacks, the current mean recommendation for CSCO is in the "buy range".
Amazon.com, Inc. (AMZN) is -0.14 at $225.55, with 2,556,339 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Jun 2025. The consensus EPS forecast is $1.32. As reported by Zacks, the current mean recommendation for AMZN is in the "buy range".
Apple Inc. (AAPL) is -0.07 at $208.55, with 2,338,289 shares traded. AAPL's current last sale is 88.74% of the target price of $235.
QXO, Inc. (QXO) is -0.23 at $20.82, with 2,336,099 shares traded. As reported by Zacks, the current mean recommendation for QXO is in the "strong buy range".
Walt Disney Company (The) (DIS) is unchanged at $119.97, with 1,921,915 shares traded. As reported by Zacks, the current mean recommendation for DIS is in the "buy range".
CVS Health Corporation (CVS) is unchanged at $64.36, with 1,738,879 shares traded. As reported by Zacks, the current mean recommendation for CVS is in the "buy range".
Medtronic plc (MDT) is unchanged at $89.73, with 1,606,451 shares traded. MDT's current last sale is 94.45% of the target price of $95.
Wells Fargo & Company (WFC) is +0.06 at $83.49, with 1,342,810 shares traded. Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Jun 2025. The consensus EPS forecast is $1.41. WFC is scheduled to provide an earnings report on 7/15/2025, for the fiscal quarter ending Jun2025. The consensus earnings per share forecast is 1.41 per share, which represents a 133 percent increase over the EPS one Year Ago
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

CVS Health Corporation

Fundamental analysis

Ratios

Valuation

Debts

Efficiency

Other ratios

Revenue

Financials

Growth

Assets

Debts